Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tat-beclin 1 D11
- Development stage
- Phase 1
- Lead developer
- Bio-Techne
- Modality
- Peptides
- Administration
- Intraperitoneal
01
Overview
Tat-beclin 1 D11 (TBD11) is a peptide drug currently in a Phase 1 clinical trial to evaluate its safety, tolerability, and pharmacokinetics in healthy adult participants. Its name suggests it is related to Beclin 1 (BECN1), a key protein involved in the regulation of autophagy. The drug is being investigated for its potential role in modulating autophagic flux, a process implicated in various neuroplastic changes associated with chronic pain.
02
Targets
GAPR-1 (Golgi-associated plant pathogenesis-related protein 1)NeuraminidaseBECN1 (Beclin-1)
Beyond the preview
Go deeper on Tat-beclin 1 D11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tat-beclin 1 D11.